Everolimus-eluting stent implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease) study.
暂无分享,去创建一个
M. Jeong | I. Seong | K. Seung | Seung‐Jung Park | S. Yun | Y. Jang | Young-Hak Kim | Hyo‐Soo Kim | Duk‐Woo Park | Jung‐Min Ahn | Cheol-Whan Lee | Seung‐Whan Lee | D. Lim | S. Rha | Soo-Jin Kang | Won-Jang Kim | Seong-Wook Park | S. Hur | Jong-Young Lee | S. Her | Haegeun Song
[1] C. Terkelsen,et al. Randomized Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients Treated With Percutaneous Coronary Intervention: The Scandinavian Organization for Randomized Trials With Clinical Outcome IV (SORT OUT IV) , 2012, Circulation.
[2] U. Khot,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.
[3] G. Levine,et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.
[4] G. Stone,et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data. , 2011, Journal of the American College of Cardiology.
[5] I. Seong,et al. Randomized Comparison of Everolimus-Eluting Stent Versus Sirolimus-Eluting Stent Implantation for De Novo Coronary Artery Disease in Patients With Diabetes Mellitus (ESSENCE-DIABETES): Results From the ESSENCE-DIABETES Trial , 2011, Circulation.
[6] M. Jeong,et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. , 2011, The New England journal of medicine.
[7] Seung‐Jung Park,et al. Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease. , 2011, Journal of the American College of Cardiology.
[8] G. Schuler,et al. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. , 2011, Journal of the American College of Cardiology.
[9] M. Mack,et al. Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial , 2010, Circulation.
[10] O. Alfieri,et al. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience. , 2010, JACC. Cardiovascular interventions.
[11] P. Serruys,et al. Long-term clinical results following stenting of the left main stem: insights from RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. , 2010, JACC. Cardiovascular interventions.
[12] Young-Hak Kim,et al. Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis. , 2010, JACC. Cardiovascular interventions.
[13] Gregg W Stone,et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. , 2010, The New England journal of medicine.
[14] P. Smits,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial , 2010, The Lancet.
[15] Seung‐Jung Park,et al. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgi , 2009, Journal of the American College of Cardiology.
[16] R. Weiss,et al. A meta-analysis of 3,773 patients treated with percutaneous coronary intervention or surgery for unprotected left main coronary artery stenosis. , 2009, JACC. Cardiovascular interventions.
[17] A. Kastrati,et al. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. , 2009, Journal of the American College of Cardiology.
[18] Young-Hak Kim,et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. , 2008, The New England journal of medicine.
[19] Patrick W Serruys,et al. A novel dedicated quantitative coronary analysis methodology for bifurcation lesions. , 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[20] D. Dudek,et al. Acute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. , 2008, Journal of the American College of Cardiology.
[21] P. Teirstein,et al. A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. , 2008, American heart journal.
[22] P. Serruys,et al. Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease: Insights From the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital Registries (RESEARCH and T-SEARCH) , 2005, Circulation.
[23] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[24] N. Lange,et al. Approximate case influence for the proportional hazards regression model with censored data. , 1984, Biometrics.
[25] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .